Integrative Research Laboratories Sweden AB (IRL AB)

IRL’s mission is to provide novel treatments in the field of primary neurodegenerative disorders.

 

IRL has an approach to discovery markedly different from most pharmaceutical companies. IRL utilizes an in vivo systems pharmacology approach based on phenotypic screening, systematically implemented and seamlessly integrated throughout the drug discovery process in a process referred to as the Integrative Screening Process (ISP)e. Phenotypic screening has proven more successful than target based screening in generating first-in-class drugs within the CNS area (Nature Reviews Drug Discovery, 2011, Jun 24).

Kategorier: Pharma

Gå till Integrative Research Laboratories Sweden AB (IRL AB)s hemsida